[分子生物学标志物作为Ⅰ-ⅡA期乳腺癌的预后因素]

[Molecular-biological markers as prognostic factors in breast cancer of I-IIA stage].

作者信息

Stepanova E V, Zagrekova E I, Ermilova V D, Turbin A D, Petrovichev N N, Vysotskaia I V, Dbar Zh N, Pashchenko N V, Baryshnikov A Iu, Lichinitser M R

机构信息

N. N. Blokhin Russian Cancer Research Center, 115478, Moscow.

出版信息

Arkh Patol. 2003 May-Jun;65(3):14-8.

PMID:12879604

Abstract

The study of molecular-biological markers for prediction of recurrence-free survival in breast cancer stage I-IIA demonstrates that high expression of thymidilate synthetase and high maximal density of microvessels are prognostically effective and that the prognosis is influenced by expression of both Bcl-2 and Bax. Low recurrence-free survival was observed in Bcl-2-/Bax patients (31%, median 44 months) while such survival was high in Bcl-2+/Bax patients (86%, median was not reached). The findings can be used for prognostication of a breast cancer clinical course.

摘要

关于预测Ⅰ-ⅡA期乳腺癌无复发生存的分子生物学标志物的研究表明，胸苷酸合成酶的高表达和微血管的最大密度具有预后意义，且Bcl-2和Bax的表达均会影响预后。在Bcl-2-/Bax患者中观察到较低的无复发生存率（31%，中位生存期44个月），而在Bcl-2+/Bax患者中该生存率较高（86%，未达到中位生存期）。这些发现可用于预测乳腺癌的临床病程。